Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemia

Area of Science:

• Genetics
• Cardiovascular Medicine
• Biochemistry

Background:

• Autosomal dominant hypercholesterolemia (ADH) significantly increases cardiovascular disease risk.
• Early diagnosis via molecular testing and family screening is crucial, yet known gene mutations are undetected in up to 40% of families.
• Current genetic screening for ADH primarily focuses on specific regions of the APOB gene.

Purpose of the Study:

• To identify novel genetic variants responsible for ADH in families with no detectable mutations in known genes.
• To investigate the functional consequences of a newly identified APOB variant.
• To expand the scope of genetic screening for ADH.

Main Methods:

• Combined linkage analysis and exome sequencing to identify genetic variants.
• Mass spectrometry to analyze low-density lipoprotein (LDL) composition and accumulation.
• Phenotypic analysis of affected individuals.

Main Results:

• A novel variant, Arg50Trp, was identified in exon 3 of the APOB gene.
• Mass spectrometry confirmed accumulation of LDL containing Arg50Trp APOB in circulation.
• This suggests impaired hepatic uptake of LDL due to the novel variant.
• This mutation is located outside the previously known mutation region in exon 26 of APOB.

Conclusions:

• The Arg50Trp variant in APOB is a newly identified cause of autosomal dominant hypercholesterolemia.
• This variant leads to defective LDL metabolism and accumulation, contributing to cardiovascular risk.
• Genetic screening for ADH should be extended to include the entire APOB gene, particularly in families with previously undetected mutations.
• Advances in sequencing technology facilitate comprehensive screening of large genes like APOB.